ATNF — 180 Life Sciences Share Price
- $1.55m
- $0.63m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | n/a | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -11338.12% | ||
Return on Equity | -355.47% | ||
Operating Margin | n/a |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 16.61 | 16.64 | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis. The Company is primary focused on program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). The Company has three product development platforms: Anti-TNF platform, SCAs platform and a7nAChR platform. Anti-TNF platform is focused on fibrosis and anti-tumor necrosis factor (anti-TNF). SCAs platform is focused on drugs which are synthetic cannabidiol (CBD) or cannabigerol (CBG) analogues (SCAs). a7nAChR platform is focused on alpha 7 nicotinic acetylcholine receptor (a7nAChR). It is conducting clinical trials only for certain indications under the anti-TNF platform. The Company is undertaking preclinical research and development activities for the SCA platform.
Directors
- Marc Feldmann CCH (76)
- Lawrence Steinman CCH (73)
- James Woody CEO (78)
- Ozan Pamir CFO (30)
- Quan Anh Vu COO
- Jonathan Rothbard CSO (69)
- Donald McGovern LED (70)
- Teresa DeLuca IND (55)
- Larry Gold IND (79)
- Francis Knuettel IND (55)
- Pamela Marrone IND (64)
- Russell Ray IND (73)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 7th, 2016
- Public Since
- June 7th, 2017
- No. of Shareholders
- 71
- No. of Employees
- 4
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 852,772
- Address
- 3000 El Camino Real, Bldg 4, Ste 200, PALO ALTO, 94306
- Web
- https://180lifesciences.com/
- Phone
- +1 6505070669
- Contact
- Jason Assad
- Auditors
- Marcum LLP
Upcoming Events for ATNF
180 Life Sciences Corp Annual Shareholders Meeting
Q2 2024 180 Life Sciences Corp Earnings Release
Similar to ATNF
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
As of Today at 19:00 UTC, shares in 180 Life Sciences are trading at $1.82. This share price information is delayed by 15 minutes.
Shares in 180 Life Sciences last closed at $1.82 and the price had moved by -92.27% over the past 365 days. In terms of relative price strength the 180 Life Sciences share price has underperformed the S&P500 Index by -93.57% over the past year.
The overall consensus recommendation for 180 Life Sciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
180 Life Sciences does not currently pay a dividend.
180 Life Sciences does not currently pay a dividend.
180 Life Sciences does not currently pay a dividend.
To buy shares in 180 Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.82, shares in 180 Life Sciences had a market capitalisation of $1.55m.
Here are the trading details for 180 Life Sciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ATNF
Based on an overall assessment of its quality, value and momentum 180 Life Sciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like 180 Life Sciences. Over the past six months, its share price has underperformed the S&P500 Index by -81.93%.
As of the last closing price of $1.82, shares in 180 Life Sciences were trading -77.2% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The 180 Life Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.82.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
180 Life Sciences' management team is headed by:
- Marc Feldmann - CCH
- Lawrence Steinman - CCH
- James Woody - CEO
- Ozan Pamir - CFO
- Quan Anh Vu - COO
- Jonathan Rothbard - CSO
- Donald McGovern - LED
- Teresa DeLuca - IND
- Larry Gold - IND
- Francis Knuettel - IND
- Pamela Marrone - IND
- Russell Ray - IND